Industry: Pharma tech
Pharmaceutical technology VC funding
Startups that build software for trials, regulatory filings, drug plants and pharma sales are raising again, often around AI. We help pharma tech founders show investors the contracts, renewals and validation behind the product.
- Funding data and investor types for trial, regulatory and pharma software
- Decks and models built on drugmaker contracts, validation and renewals
- Waveup prepares investor materials for pharma technology companies: $3B+ raised for 600+ startups since 2014
In short
What is pharmaceutical technology VC funding?
Pharmaceutical technology VC funding is venture money for companies that sell software and data to drugmakers. It covers trial platforms, regulatory and safety software, commercial tools and plant systems. Clinical trial tech raised $1.04B in 2026 to early November, by Tracxn's count. This page is for founders building these tools, not for drugmakers buying them.
- Who it's for
- Companies building trial, regulatory, commercial and manufacturing software for drugmakers, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Are investors funding pharma tech again in 2026?
Yes. By early November 2026, clinical trial tech had raised more than in 2024 and 2025 combined, by Tracxn's count.
The opportunity
Drugmakers want faster, cheaper trials, and regulators are making room for new tools.
- New good clinical practice rules, in force in the EU, favour risk-based, fit-for-purpose trials
- FDA guidance now covers trial visits by telehealth, at home or with local doctors
- The FDA has set out guiding principles for good AI practice in drug development
The problem
Funding for trial technology fell for four years after 2021. Tracxn counts $365M raised in 2025.
Market size
How big is pharma software, and what is moving it?
Veeva makes cloud software for the life sciences industry. It earned $3.20B in fiscal 2026, the year to 31 January. Four shifts shape what drugmakers buy next:
- Trial volume: nearly 32,000 interventional trials were first posted on ClinicalTrials.gov in 2025, by our count
- One EU portal: since 31 January 2025, every running EU trial must be recorded in CTIS
- AI in filings: the FDA's drug centre has seen more than 500 submissions with AI components, 2016 to 2023
- US plants: only 11% of active-ingredient makers for FDA-approved drugs are American, and FDA's PreCheck helps new plants prepare
Venture capital
Is venture money returning to clinical trial tech?
Funding for clinical trial technology peaked in 2021, then shrank each year to 2025. By early November 2026 it had passed $1B again, by Tracxn's count.
of equity raised by clinical trial tech companies in 2026 to October, up from $205M a year earlier
paid in cash by Thermo Fisher for Clario, a clinical trial data company, at closing in March 2026
Series A for Biorce, a Barcelona startup that uses AI to plan trials, in February 2026
Who invests in pharma tech startups?
Venture arms of companies in the drug business, B2B software VCs and private equity. Five examples follow; for more names, see our lists of healthcare venture capital firms and B2B SaaS venture capital firms.
Investor database
Pharma investors in our database
The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by pharma investments
Investments by industry
- Healthtech & Wellness48%
- Biotech24%
- Pharma21%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- $500K–$1M$1M–$3M$3M–$10M$10M–$50M
- Based in
- New York, United States
- Invests in
- East Asia, USA
704 investments in total, 21 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness42%
- Biotech26%
- Pharma18%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $100K–$500K$500K–$1M
- Based in
- Cambridge, United States
- Invests in
- Southeast Asia, USA
613 investments in total, 17 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness45%
- Biotech30%
- Pharma19%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Menlo Park, United States
- Invests in
- Europe, USA, Canada
382 investments in total, 13 tagged Pharma.Open the full fund profile
Investments by industry
- Software & Apps36%
- AI & Deep Tech17%
- Healthtech & Wellness16%
- Pharma3%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $3M–$10MOver $50M$10M–$50M
- Based in
- Boston, United States
315 investments in total, 6 tagged Pharma.Open the full fund profile
Investments by industry
- Software & Apps29%
- Healthtech & Wellness19%
- AI & Deep Tech7%
- Pharma5%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $500K–$1M$1M–$3M$3M–$10M$10M–$50M
- Based in
- Menlo Park, United States
- Invests in
- USA
2225 investments in total, 5 tagged Pharma.Open the full fund profile
From our investor database.
What do investors question first in pharma tech?
Our Fundraising 2025 study asked 56 VCs why they pass. Revenue growth, unit economics, burn and missed milestones came first, then defensibility and crowded categories. Pharma tech founders face four questions of their own.
Few buyers, slow deals
Pharma software sells to a short list of large drugmakers. Veeva's top 10 customers brought in 28% of its revenue in fiscal 2026.
What investors ask
- How many large drugmakers have signed, and how long did each contract take?
What your deck shows
- Signed contracts, renewals and sales cycle length by customer
- A route to mid-size biotechs and CROs too
Trials beyond the site
Science 37, a Nasdaq-listed company that took trials beyond traditional sites, agreed in January 2024 to sell to eMed. The deal valued its equity at about $38 million.
What investors ask
- Will sponsors pay for this on every study, or only for some trials?
What your deck shows
- Revenue per study and how many sponsors come back
- Gross margin after home visits, devices and staff
AI a regulator can trust
In January 2025 the FDA drafted guidance on using AI to support regulatory decisions on drugs. Sponsors now ask how a model's output will hold up in review.
What investors ask
- Can your output go into a regulatory submission, and has it already?
What your deck shows
- Validation records and an audit trail for each model
- Studies or filings where sponsors used your output
Suites that add the same feature
Veeva is adding AI agents to its own applications. Its subscription revenue grew 17% in fiscal 2026.
What investors ask
- What stops Veeva, IQVIA or Medidata from adding this to their suites?
What your deck shows
- A task the suites leave undone, with customer proof
- Connectors that let you sell alongside them
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
What your product saves a drugmaker in time, cost or risk, with proof.
Contract value, set-up fees, renewals and AI costs, month by month.
A range checked against pharma software deals and listed peers.
Health VCs, venture arms of pharma and lab groups, and growth funds.
Validation files, security reviews and customer contracts, ready to check.
For a sale to a lab group, a CRO, a software suite or a buyout fund.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.
About usPharmaceutical technology VC funding FAQ
What is pharma tech?
How do pharma tech startups get funding?
How much venture capital goes into clinical trial tech in 2026?
What do investors look for in a pharma tech startup?
Who buys pharma tech companies?
How much does help with a pharma tech raise cost?
Raising for a pharma tech company?
Tell us who uses your software at drugmakers and what they pay. We'll show you what investors will check before a term sheet.



